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Abstract
Interactions between the conceptus and the mother are bi-directional: the feto-placental tissues need nutrition and a
suitable environment in homeostatic condition whereas the mother influenced by the placental factors adapts her
metabolism and immune system. Many different mechanisms acting locally or at distance ensure tolerance of the semi-
allogeneic graft by the maternal natural and adaptive immune defences. In front of this tolerance, mechanisms exist
ensuring rejection of the conceptus by the mother (spontaneous abortion) through rupture of one or more tolerance
mechanisms, notably in stress situations endangering the mother. Thus outcome of a pregnancy is dependent on
efficiently working tolerance mechanisms, and rupture of such mechanisms can lead to rejection. The balance of
influence leading either to tolerance or rejection is under control of internal (maternal and fetal) and external
(environmental) factors. Rejection, if triggered, mainly occurs through immune-induced inflammation, tissue
degradation and coagulation.
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1. Between tolerance and rejection
An embryo is a mating product of histo-
incompatible individuals in an outbred popula-
tion. It can be compared with a semi-allogeneic
graft which has to be tolerated over all the
gestational period (for review see Thellin et al.,
2000).
Intimate contacts between the foetus and the
maternal tissues ensure nutrition of the fetus and
adaptation of the mother to this graft. The
placenta, composed of fetal and maternal struc-
tures, is both a barrier and a zone for intense
exchanges. On one hand, due to the paternal
antigens, which the fetus is susceptible to express,
the maternal immune system risks at each time to
induce rejection. The maternal immune system is
aware of the presence of the fetus and the placenta
and can be induced to reject this graft (Erlebacher,
2001). Thus tolerance mechanisms have evolved
during evolution to insure the maintenance of the
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feto-placental graft. On the other hand, evolution
has retained means to reject the fetus in case of
stress endangering the mother, for example, during
a severe infectious condition.
In consequence, the feto-placental graft is toler-
ated or rejected by the maternal immune system.
Besides any fetal inadequacy, the decision is
notably dependent on environmental parameters,
namely on the presence of toxic substances,
infectious agents or physical or psychological
aggressions.
2. Means of tolerance
A lot of hypotheses to explain fetal tolerance
have been developed and investigated for 50 years.
The mechanisms of fetal tolerance are plural and
working at different periods of time in embryonic
and fetal development. These tolerance mechan-
isms act at distance on the maternal immune
system or locally at the placental level.
Systemic effects are due to immuno-active
hormones, but also fetal antigens and cells circu-
lating in the maternal blood vessels. Indeed,
progesterone, an hormone synthesized in large
quantities by the placenta, is able to lower immune
responses (Siiteri and Stites, 1982). Other hor-
mones, such as the placental growth hormone
which replaces progressively the pituitary growth
hormone during pregnancy (Hennen et al., 1985),
might also help to modulate the immune system
(Thellin et al., 2000). Anergy, also called periph-
eral tolerance, might be induced by fetal antigens
or whole cells passing into the maternal blood
circulation and the peripheral lymph organs.
Indeed, in absence of inflammatory signals such
antigens can act as tolerogens.
Locally at the placental level, many different
mechanisms are involved, working alone or in
interaction with each other. Major histocompat-
ibility complex (MHC) class I expression is
reduced on the syncytiotrophoblast. Its specific
expression of human leukocyte antigen-G (HLA-
G) may block the cytolytic activity of natural killer
(NK) cells (Moreau et al., 1998), (Fig. 1). In
addition to the low MHC expression, antigens
could be masked by camouflage systems (Thellin
et al., 2000). Leukemia inhibitory factor (LIF) and
its receptor are essential for implantation and are
thought helping trophoblastic growth or differen-
tiation (Fig. 2a, b), (Senturk and Arici, 1998).
Complement inhibitory mechanisms are ensured
by blocking molecules, such as MCP (membrane
complement protein), DAF (decay accelerating
factor (Fig. 3), (Johnson et al., 1990; Holmes et
al., 1990) or other factors (i.e. Crry in rodents: Xu
Fig. 1. HLA-G. HLA-G may inhibit cytolytic activity of NK
cells by binding their KIR receptors (modified from Thellin et
al., 2000).
Fig. 2. LIF. (a) LIF (by endometrium) and its receptor (on
blastocyst) are essential for implantation. (b) After implanta-
tion, LIF could influence the growth and differentiation of
trophoblasts (modified from Thellin et al. 2000).
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et al., 2000). Indoleamine 2, 3 dioxygenase (IDO)
catabolizes tryptophan which is necessary for
lymphoid cell activation. It is produced by the
syncytiotrophoblast and reduces close-range im-
mune cell reactions (Fig. 4), (Munn et al., 1998).
The CD95/CD95-ligand system in involved in
cellular turnover, tumor cell elimination, antiviral
responses or protection of tissues against activated
lymphocytes. It might be active in controlling
trophoblastic growth and elimination of cells
endangering trophoblastic cells (Fig. 5), Coumans
et al., 1999; Runic et al., 1998). This without
endangering the trophoblasts themselves. Indeed,
CD95 present on trophoblasts does not seem to
transduce apoptotic signals in these cells (Payne et
al., 1999). Annexin II is secreted by the placenta
and might inhibit lymphoproliferation and secre-
tion of maternal immunoglobulins (Fig. 6), (Aarli
and Matre, 1998).
Th1/Th2 balance is in favor of Th2 cells which
produce IL4, IL5, IL6, IL9, IL10, TGFb and
reduce the production of pro-inflammatory mole-
cules, like IL2 and IFNg, which can endanger fetus
survival (Raghupathy, 1997; Clark et al., 1999).
Recent data presented below suggest that this
balance could be a critical and a complex actor
in the conceptus tolerance.
The immune cell population at the placental
level has also shown some peculiarities. Indeed, the
products and surface markers of these cells may
differ from generally encountered immune cells of
the same types. For example, decidual macro-
phages are alternatively activated macrophages
exerting anti-inflammatory actions. These cells
produce little reactive oxygen derivates, but IL10
and IL1-R antagonist (Goerdt and Orfanos, 1999).
Fig. 3. Complement. Inhibition of complement (by destruction
or binding) would reduce its availability to harm fetal tissues
(modified from Thellin et al., 2000).
Fig. 4. IDO. IDO is produced by the trophoblast and
catabolizes tryptophane at short range and may so inhibit close
maternal immune cells (modified from Thellin et al., 2000).
Fig. 5. CD95/CD95-L. Syncytiotrophoblastic CD95-L (mem-
brane or soluble form) can induce apoptosis in maternal
immune cells, but not syncytiotrophoblastic cells, expressing
CD95 (modified from Thellin et al., 2000).
Fig. 6. Annexin II. The Annexin II secreted by the placenta
could inhibit lymphoproliferation and secretion of maternal
immunoglobulins (modified from Thellin et al., 2000).
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Placental VgdT cells are activated to produce the
immunosuppressive IL10 and TGFb2; in humans
NK-gdT cells appear to be the main source of
TGFb2 (Clark et al., 2001b). IL10 and TGFb are
inhibitors of the Th1 response. The diversity of
gdT cells in maternal tissue during pregnancy
contrasts with a limited TCR subtype diversity in
the non-pregnant state (Bonney et al., 2000; Clark
et al., 1999). Many other T, NK and NKT cells are
present in the deciduas; the identification of their
roles requires further research. These cells also
play a part in other fields than tolerance, for
example, uterine NK producing interferon gamma
contribute to implantation (Ashkar and Croy,
1999). Production of OX-2, a glycoprotein which
pushes gdTh1/gdTh2 balance toward gdTh2, also
inhibits macrophages and decreases fgl2, a pro-
thrombinase able to trigger abortion by placental
thrombosis and activation of the complement (Fig.
7), (Clark et al., 2001a).
3. Means for fetal rejection
By definition, rejection happens when critical
tolerance mechanisms are absent or severed.
Genotypic or phenotypic alterations can make
one or both of the parents unable to conceive,
temporarily or definitely. Depending of the altera-
tion, the problem can occur at different steps of
the pregnancy, from the fecundation to post-
implantation development. The post-implantation
rejection is the one most potent to be detected.
While the event initiating rejection may widely
vary, most of them could act partly through
similar ways. A most important inducible way of
rejection involves a Th1/Th2 imbalance toward Th1,
increasing the production of Th1 cytokines, nota-
bly the pro-inflammatory IFNg, TNFa and IL2
(Hill et al., 1995). Th1 cytokines can activate
inflammatory macrophages and NK cells into
lectin-activated killers (LAK), which then exert
cytolytic capacities. Th1 cytokines can also act
directly on trophoblastic cells, reducing OX-2
production and increasing their production of fgl
2 (pro-thrombinase). Fgl 2 can then induce clot-
ting, which blocks the circulation of maternal
blood in the placenta (thrombosis), thus the vital
exchanges between the maternal and fetal bloods.
This leads to the death of fetal tissues. Thrombin-
triggered IL8-production in endothelial cells may
attract and activate (Fig. 7) neutrophils, which
attack feto-placental structures. Th1 cytokines also
stimulate the production of immunoglobulins able
to activate the complement cascade. Failure to
reduce complement capacity contributes then to
the abortion process.
This Th1 imbalance can be triggered mainly by
infection and stress. Infections leading to a Th1
shift alter syncytiotrophoblastic secretory activities
thus reduce the protective tolerance mechanisms.
TNFa and IFNg, able to act directly on syncytio-
trophoblasts, appear to be the effectors inducing
spontaneous abortions in stress situations leading
to coagulation, arrest of the local maternal blood
flow, and aggression of the feto-placental struc-
tures (Clark and Croitoru, 2001).
Other factors are also potent to trigger rejection,
via Th1 imbalance or not. Hormones or inhibitory
molecules can counteract the placental hormones
which sustain Th2-type immune responses. For
example, release of substance P under stress (and
probably other circumstances) from neurons in the
uterus induces IL1, TNFa and IFNg production
Fig. 7. OX-2 and fgl2. In dark: during normal pregnancy,
trophoblastic OX-2 inhibits fgl2 expression. In grey: when Th1
cytokine expression is activated (by stress or LPS notably), fgl2
expression is increased in the placenta. Fgl2 inhibit OX-2
expression and convert pro-thrombin into thrombin. On one
side, thrombin then activates IL-8 synthesis in endothelial cells.
IL-8 attracts polymorphonuclear leucocytes (PMNL) leading
also to an activation of the complement. On the other side,
thrombin triggers clotting via fibrin deposition, terminating the
blood flow in placenta. If severe, these events can trigger
abortion.
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(Clark et al., 1999). Toxic substances altering
metabolism or vascularization disturb placental
development and expressions, thus could decrease
or block mechanisms of tolerance, therefore,
improve chances of rejection. In consequence,
toxic factors risk to alter not only fetal cells, but
also maternal functions, namely the tolerance
mechanisms.
General modulators of the immune response,
for example activators of lymphocytes, macro-
phages, NK cells, neutrophils, of complement
cascade or MHC class I or class II expression
may initiate rejection mechanisms. Indeed, the
lipopolysaccharides (LPS) released from bacterial
membranes during infections are potent activators
of immune cells (Arck et al., 1997; Kohmura et al.,
2000). Peri-implantation losses in mice, analogous
to occult losses in humans, are dependent upon
cells producing perforin and complement cascade
initiation but not on TNFa or pro-coagulant
activation as observed during abortion of vascu-
larized placenta, analogous to clinically evident
human spontaneous miscarriage (Clark et al.,
2001b). Thus rejection inducers and effectors differ
as related to the evolutionary stage of the con-
ceptus.
4. Conclusions
The feto-placental entity has been compared
with a graft, a tumor or a parasite in conceptual
models (for review see Clark et al., 1999). How-
ever, even though mechanisms allowing tolerance
can also play roles in graft tolerance, non-rejection
of tumors or persistence of parasites, the feto-
placental entity creates its own hormonal ambi-
ence profoundly influencing its own or the mater-
nal syntheses. At difference with grafts, tumors or
parasites, the feto-placental graft can be discarded
if factors endangering the mother dominate,
notably through Th1 response of the immune
system. This finely tuned situation, which on one
hand favors conceptus tolerance, but on the other
hand allows its rejection, is influenced by internal
and external factors. Lots of progress have been
accomplished recently in the comprehension of the
mechanisms of tolerance or rejection. Current
research on the subject will help identify more
precisely the factors putting a pregnancy at risk
and lead to develop means to circumvent these
factors as much as possible.
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